{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T17:43:35Z","timestamp":1779903815780,"version":"3.53.1"},"reference-count":159,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T00:00:00Z","timestamp":1768176000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pathogens"],"abstract":"<jats:p>Acinetobacter baumannii has been characterized by CDC, WHO and most National Healthcare Systems worldwide as a critical nosocomial pathogen, and classified as an ESKAPE (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, Enterobacter spp.) pathogen. Mortality of invasive infections due to A. baumannii exceeds 40%. To highlight its impact on public health, ECDC has organized a special project on national lab co-ordination to accurately detect and report carbapenem-resistant strains, to identify epidemiological factors for infection (or colonization) with carbapenem-resistant A. baumanii at clonal and sub-genomic level. This review aims to describe the history, epidemiology, and evolution of resistance of A. baumannii, and stress the caveats associated with the management of systemic infections. Available active antimicrobials and drugs in the pipeline are listed, and available clinical evidence on their pharmacokinetics and efficacy in various types of infections are described. Clinician\u2019s choice of treatment (drug, and monotherapy vs. combination treatment) depends on the patients\u2019 profile, site of infection and antimicrobial resistance profile. Emphasis is laid on specific patient subpopulations, whose management is discussed.<\/jats:p>","DOI":"10.3390\/pathogens15010081","type":"journal-article","created":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T10:25:23Z","timestamp":1768213523000},"page":"81","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Treating Extensively Drug-Resistant Acinetobacter baumannii: Considerations for Host Characteristics and Type of Infections"],"prefix":"10.3390","volume":"15","author":[{"given":"Anastasia","family":"Geladari","sequence":"first","affiliation":[{"name":"Infectious Diseases Unit, Hippokration General Hospital, 54642 Thessaloniki, Greece"},{"name":"3rd Pediatric Department, Aristotle University, 54642 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-7732-709X","authenticated-orcid":false,"given":"Dimitrios","family":"Kouroupis","sequence":"additional","affiliation":[{"name":"2nd Propedeutic Department of Internal Medicine, Aristotle University, Hippokration General Hospital, 54642 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyriaki","family":"Vafeidou","sequence":"additional","affiliation":[{"name":"2nd Propedeutic Department of Internal Medicine, Aristotle University, Hippokration General Hospital, 54642 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-1221-6618","authenticated-orcid":false,"given":"Vasileios","family":"Liakos","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, Hippokration General Hospital, 54642 Thessaloniki, Greece"},{"name":"3rd Pediatric Department, Aristotle University, 54642 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Magoudi","sequence":"additional","affiliation":[{"name":"2nd Propedeutic Department of Internal Medicine, Aristotle University, Hippokration General Hospital, 54642 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastasia-Izampella","family":"Papathanasiou","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, Hippokration General Hospital, 54642 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9881-451X","authenticated-orcid":false,"given":"Elias","family":"Iosifidis","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, Hippokration General Hospital, 54642 Thessaloniki, Greece"},{"name":"3rd Pediatric Department, Aristotle University, 54642 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0202-364X","authenticated-orcid":false,"given":"Emmanuel","family":"Roilides","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, Hippokration General Hospital, 54642 Thessaloniki, Greece"},{"name":"3rd Pediatric Department, Aristotle University, 54642 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charalampos","family":"Antachopoulos","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, Hippokration General Hospital, 54642 Thessaloniki, Greece"},{"name":"3rd Pediatric Department, Aristotle University, 54642 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6906-2504","authenticated-orcid":false,"given":"Athina","family":"Pyrpasopoulou","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, Hippokration General Hospital, 54642 Thessaloniki, Greece"},{"name":"2nd Propedeutic Department of Internal Medicine, Aristotle University, Hippokration General Hospital, 54642 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,1,12]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1128\/br.37.4.522-561.1973","article-title":"Moraxella, Acinetobacter, and the Mimeae","volume":"37","author":"Henriksen","year":"1973","journal-title":"Bacteriol. Rev."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1128\/CMR.00058-07","article-title":"Acinetobacter baumannii: Emergence of a successful pathogen","volume":"21","author":"Peleg","year":"2008","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_3","first-page":"722","article-title":"Etudes de syst\u00e9matique bact\u00e9rienne. X. R\u00e9vision des especes r\u00e9unies dans le genre Achromobacter [Studies on bacterial taxonomy. X. The revision of species under Acromobacter group]","volume":"86","author":"Brisou","year":"1954","journal-title":"Ann. Inst. Pasteur"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1128\/jb.95.5.1520-1541.1968","article-title":"A study of the Moraxella group. II. Oxidative-negative species (genus Acinetobacter)","volume":"95","author":"Baumann","year":"1968","journal-title":"J. Bacteriol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1099\/00207713-36-2-228","article-title":"Taxonomy of the Genus Acinetobacter with the Recognition of Acinetobacter baumannii sp. nov. Acinetobacter haemolyticus sp. nov. Acinetobacter johnsonii sp. nov. and Acinetobacter junii sp. nov. and Emended Descriptions of Acinetobacter calcoaceticus and Acinetobacter lwofii","volume":"36","author":"Bouvet","year":"1986","journal-title":"Int. J. Syst. Bacteriol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1038\/nrmicro1789","article-title":"An increasing threat in hospitals: Multidrug-resistant Acinetobacter baumannii","volume":"5","author":"Dijkshoorn","year":"2007","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1128\/JCM.36.7.1938-1941.1998","article-title":"Survival of Acinetobacter baumannii on dry surfaces: Comparison of outbreak and sporadic isolates","volume":"36","author":"Jawad","year":"1998","journal-title":"J. Clin. Microbiol."},{"key":"ref_8","first-page":"119","article-title":"Biofilm formation in Acinetobacter baumannii","volume":"37","author":"Longo","year":"2014","journal-title":"New Microbiol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1007\/s00284-022-03071-5","article-title":"Acinetobacter baumannii Biofilm Formation: Association with Antimicrobial Resistance and Prolonged Survival under Desiccation","volume":"79","author":"Choudhary","year":"2022","journal-title":"Curr. Microbiol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1128\/CMR.9.2.148","article-title":"Acinetobacter spp. as nosocomial pathogens: Microbiological, clinical, and epidemiological features","volume":"9","author":"Towner","year":"1996","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_11","unstructured":"WHO (2024). WHO Bacterial Priority Pathogens List, 2024: Bacterial Pathogens of Public Health Importance to Guide Research, Development and Strategies to Prevent and Control Antimicrobial Resistance, WHO."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1038\/s41598-022-26009-0","article-title":"The prevalence, presentation and outcome of colistin susceptible-only Acinetobacter baumannii-associated pneumonia in intensive care unit: A multicenter observational study","volume":"13","author":"Wang","year":"2023","journal-title":"Sci. Rep."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.jinf.2019.09.012","article-title":"The global prevalence of multidrug-resistance among Acinetobacter baumannii causing hospital-acquired and ventilator-associated pneumonia and its associated mortality: A systematic review and meta-analysis","volume":"79","author":"Liew","year":"2019","journal-title":"J. Infect."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"136","DOI":"10.4269\/ajtmh.23-0820","article-title":"Case Report: Severe Community-Acquired Pneumonia in R\u00e9union Island due to Acinetobacter baumannii","volume":"111","author":"Rotini","year":"2024","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1093\/clinids\/14.1.83","article-title":"Community-acquired Acinetobacter pneumonia in the Northern Territory of Australia","volume":"14","author":"Anstey","year":"1992","journal-title":"Clin. Infect. Dis."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1111\/j.1440-1843.2009.01630.x","article-title":"Severe community-acquired Acinetobacter baumannii pneumonia: An emerging highly lethal infectious disease in the Asia-Pacific","volume":"14","author":"Ong","year":"2009","journal-title":"Respirology"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Nutman, A., Temkin, E., Wullfhart, L., Schechner, V., Schwaber, M.J., and Carmeli, Y. (2023). Acinetobacter baumannii Bloodstream Infections: A Nationwide Study in Israel. Microorganisms, 11.","DOI":"10.3390\/microorganisms11092178"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1086\/314040","article-title":"Nosocomial bloodstream infections caused by Acinetobacter species in United States hospitals: Clinical features, molecular epidemiology, and antimicrobial susceptibility","volume":"31","author":"Wisplinghoff","year":"2000","journal-title":"Clin. Infect. Dis."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"5699","DOI":"10.2147\/IDR.S484546","article-title":"Risk Factors for Development and Mortality of Bloodstream Infections Caused by Carbapenem-Resistant Acinetobacter baumannii","volume":"17","author":"Li","year":"2024","journal-title":"Infect. Drug Resist."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"107605","DOI":"10.1016\/j.micpath.2025.107605","article-title":"Acinetobacter baumannii: A comprehensive review of global epidemiology, clinical implications, host interactions, mechanisms of antimicrobial resistance and mitigation strategies","volume":"204","author":"Sharma","year":"2025","journal-title":"Microb. Pathog."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.ajic.2017.08.037","article-title":"Prospective surveillance of device-associated health care-associated infection in an intensive care unit of a tertiary care hospital in New Delhi, India","volume":"46","author":"Kumar","year":"2018","journal-title":"Am. J. Infect. Control"},{"key":"ref_22","first-page":"e000306","article-title":"Emergence, molecular mechanisms and global spread of carbapenem-resistant Acinetobacter baumannii","volume":"5","author":"Hamidian","year":"2019","journal-title":"Microb. Genom."},{"key":"ref_23","unstructured":"World Health Organization (WHO) (2017). Global Priority List of Antibiotic-Resistant Bacteria to Guide Research, Discovery, and Development of New Antibiotics, World Health Organization (WHO)."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.2147\/IDR.S257851","article-title":"Trend and Characteristics of Acinetobacter baumannii Infections in Patients Attending Universal College of Medical Sciences, Bhairahawa, Western Nepal: A Longitudinal Study of 2018","volume":"13","author":"Raut","year":"2020","journal-title":"Infect. Drug Resist."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Kim, S.-H., and Mun, S.J. (2025). Comparative Analysis of Clinical Characteristics and Antimicrobial Resistance Between Acinetobacter baumannii and Other Acinetobacter Species. Pathogens, 14.","DOI":"10.3390\/pathogens14010046"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1007\/BF02818801","article-title":"Characteristics of clinical Acinetobacter spp. Strains","volume":"47","year":"2002","journal-title":"Folia Microbiol."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Ayoub Moubareck, C., and Hammoudi Halat, D. (2020). Insights into Acinetobacter baumannii: A review of microbiological, virulence, and resistance traits in a threatening nosocomial pathogen. Antibiotics, 9.","DOI":"10.3390\/antibiotics9030119"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"127057","DOI":"10.1016\/j.micres.2022.127057","article-title":"Insights into mucoid Acinetobacter baumannii: A review of microbiological characteristics, virulence, and pathogenic mechanisms in a threatening nosocomial pathogen","volume":"261","author":"Kan","year":"2022","journal-title":"Microbiol. Res."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"ofab386","DOI":"10.1093\/ofid\/ofab386","article-title":"Increased capsule thickness and hypermotility are traits of carbapenem-resistant Acinetobacter baumannii ST3 strains causing fulminant infection","volume":"8","author":"Rakovitsky","year":"2021","journal-title":"Open Forum Infect. Dis."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Kebriaee, A.N., Behzadi, P., Mohammadian, T., Fooladi, A.A.I., and Hosseini, M.S. (2025). Distribution of antimicrobial resistance genes and virulence genes in different genotypes of Acinetobacter baumannii. BMC Infect. Dis., 25.","DOI":"10.1186\/s12879-025-11632-9"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Szemraj, M., Piechota, M., Olszowiec, K., Wicha, J., Pruss, A., Sienkiewicz, M., Witeska, M., Szweda, P., and Kot, B. (2025). High Prevalence of Virulence and blaOXA Genes Encoding Carbapenemases Among Acinetobacter baumannii Isolates from Hospitalised Patients in Three Regions of Poland. Pathogens, 14.","DOI":"10.3390\/pathogens14080731"},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Scoffone, V.C., Trespidi, G., Barbieri, G., Arshad, A., Israyilova, A., and Buroni, S. (2025). The Evolution of Antimicrobial Resistance in Acinetobacter baumannii and New Strategies to Fight It. Antibiotics, 14.","DOI":"10.3390\/antibiotics14010085"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"S166","DOI":"10.1093\/cid\/ciad109","article-title":"Global Epidemiology and Mechanisms of Resistance of Acinetobacter baumannii-calcoaceticus Complex","volume":"76","author":"Castanheira","year":"2023","journal-title":"Clin. Infect. Dis."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Cain, A.K., and Hamidian, M. (2023). Portrait of a killer: Uncovering resistance mechanisms and global spread of Acinetobacter baumannii. PLoS Pathog., 19.","DOI":"10.1371\/journal.ppat.1011520"},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Lee, C.R., Lee, J.H., Park, M., Park, K.S., Bae, I.K., Kim, Y.B., Cha, C.-J., Jeong, B.C., and Lee, S.H. (2017). Biology of Acinetobacter baumannii: Pathogenesis, Antibiotic Resistance Mechanisms, and Prospective Treatment Options. Front. Cell. Infect. Microbiol., 7.","DOI":"10.3389\/fcimb.2017.00055"},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Vrancianu, C.O., Gheorghe, I., Czobor, I.B., and Chifiriuc, M.C. (2020). Antibiotic Resistance Profiles, Molecular Mechanisms and Innovative Treatment Strategies of Acinetobacter baumannii. Microorganisms, 8.","DOI":"10.3390\/microorganisms8060935"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Kyriakidis, I., Vasileiou, E., Pana, Z.D., and Tragiannidis, A. (2021). Acinetobacter baumannii Antibiotic Resistance Mechanisms. Pathogens, 10.","DOI":"10.3390\/pathogens10030373"},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Shi, J., Cheng, J., Liu, S., Zhu, Y., and Zhu, M. (2024). Acinetobacter baumannii: An evolving and cunning opponent. Front. Microbiol., 15.","DOI":"10.3389\/fmicb.2024.1332108"},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Marino, A., Augello, E., Stracquadanio, S., Bellanca, C.M., Cosentino, F., Spampinato, S., Cantarella, G., Bernardini, R., Stefani, S., and Cacopardo, B. (2024). Unveiling the Secrets of Acinetobacter baumannii: Resistance, Current Treatments, and Future Innovations. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25136814"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1186\/s13613-025-01580-7","article-title":"Outcomes of carbapenem-resistant Acinetobacter baumannii bloodstream infections in intensive care units and prognostic effect of different antimicrobial regimens","volume":"15","author":"Chen","year":"2025","journal-title":"Ann. Intensive Care"},{"key":"ref_41","unstructured":"(2025, October 26). Antimicrobial Resistance in the EU\/EEA (EARS-Net)\u2014Annual Epidemiological Report 2023. Available online: https:\/\/www.ecdc.europa.eu\/en\/publications-data\/antimicrobial-resistance-eueea-ears-net-annual-epidemiological-report-2023."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Sharma, S., Banerjee, T., Yadav, G., and Kumar, A. (2023). Susceptibility profile of bla OXA-23 and metallo-\u03b2-lactamases co-harbouring isolates of carbapenem resistant Acinetobacter baumannii (CRAB) against standard drugs and combinations. Front. Cell. Infect. Microbiol., 12.","DOI":"10.3389\/fcimb.2022.1068840"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"e0137925","DOI":"10.1128\/spectrum.01379-25","article-title":"In vitro activity of sulbactam in combination with other antimicrobial agents against extensively drug-resistant Acinetobacter baumannii","volume":"13","author":"Jitmuang","year":"2025","journal-title":"Microbiol. Spectr."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Huralska, M., Pogue, J.M., Rybak, M., Abdul-Mutakabbir, J.C., Stamper, K., Marchaim, D., Thamlikitkul, V., Carmeli, Y., Chiu, C.H., and Daikos, G. (2025). The Impact of Synergistic Therapy Between Colistin and Meropenem on Outcomes of Patients with Pneumonia or Bloodstream Infection due to Carbapenem-Resistant Gram-Negative Pathogens. Clin. Infect. Dis., ciaf398.","DOI":"10.1093\/cid\/ciaf398"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1556\/030.2025.02655","article-title":"Shifting molecular epidemiology of carbapenem-resistant Klebsiella pneumoniae in a regional Greek hospital: Department-specific trends and national context (2022\u20132024)","volume":"72","author":"Tsolakidou","year":"2025","journal-title":"Acta Microbiol. Immunol. Hung."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s11033-023-08982-5","article-title":"Colistin resistance in carbapenem non-susceptible Acinetobacter baumannii in a tertiary care hospital in India: Clinical characteristics, antibiotic susceptibility and molecular characterization","volume":"51","author":"Rout","year":"2024","journal-title":"Mol. Biol. Rep."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Karakalpakidis, D., Papadopoulos, T., Paraskeva, M., Tsitlakidou, M.-E., Vagdatli, E., Katsifa, H., Beloukas, A., Kotzamanidis, C., and Kottaridi, C. (2025). When the Last Line Fails: Characterization of Colistin-Resistant Acinetobacter baumannii Reveals High Virulence and Limited Clonal Dissemination in Greek Hospitals. Pathogens, 14.","DOI":"10.3390\/pathogens14080730"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ijantimicag.2004.10.001","article-title":"Evaluation of colistin as an agent against multi-resistant Gram-negative bacteria","volume":"25","author":"Li","year":"2005","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1080\/22221751.2020.1754133","article-title":"Colistin and its role in the Era of antibiotic resistance: An extended review (2000\u20132019)","volume":"9","author":"Zhong","year":"2020","journal-title":"Emerg. Microbes Infect."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1007\/s40262-017-0561-1","article-title":"Clinical Pharmacokinetics and Pharmacodynamics of Colistin","volume":"56","author":"Marchand","year":"2017","journal-title":"Clin. Pharmacokinet."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"254","DOI":"10.36519\/idcm.2025.608","article-title":"Risk Factors for Mortality in Patients Treated with Colistin Monotherapy for Carbapenem-Resistant Acinetobacter baumannii Infections","volume":"7","author":"Katip","year":"2025","journal-title":"Infect. Dis. Clin. Microbiol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"7795096","DOI":"10.1155\/2021\/7795096","article-title":"Colistin-Induced Acute Kidney Injury and the Effect on Survival in Patients with Multidrug-Resistant Gram-Negative Infections: Significance of Drug Doses Adjusted to Ideal Body Weight","volume":"2021","author":"Arrayasillapatorn","year":"2021","journal-title":"Int. J. Nephrol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"e0198123","DOI":"10.1128\/spectrum.01981-23","article-title":"Trends in the susceptibility of U.S. Acinetobacter baumannii-calcoaceticus species complex and Stenotrophomonas maltophilia isolates to minocycline, 2014\u20132021","volume":"11","author":"Pfaller","year":"2023","journal-title":"Microbiol. Spectr."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s40121-017-0153-2","article-title":"Minocycline for the Treatment of Multidrug and Extensively Drug-Resistant A. baumannii: A Review","volume":"6","author":"Lashinsky","year":"2017","journal-title":"Infect. Dis. Ther."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"e01809-20","DOI":"10.1128\/AAC.01809-20","article-title":"Pharmacokinetic and pharmacodynamic profiling of minocycline for injection following a single infusion in critically Ill adults in a phase IV open-label multicenter study (ACUMIN)","volume":"65","author":"Lodise","year":"2021","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1186\/s13054-017-1916-6","article-title":"Antimicrobials for the treatment of drug-resistant Acinetobacter baumannii pneumonia in critically ill patients: A systemic review and Bayesian network meta-analysis","volume":"21","author":"Jung","year":"2017","journal-title":"Crit. Care"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"111","DOI":"10.3947\/ic.2024.0110","article-title":"Minocycline Susceptibility of Carbapenem-Resistant Acinetobacter baumannii Blood Isolates from a Single Center in Korea: Role of tetB in Resistance","volume":"57","author":"Kim","year":"2025","journal-title":"Infect. Chemother."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"e01699-19","DOI":"10.1128\/AAC.01699-19","article-title":"In vitro activity of eravacycline against gram-negative bacilli isolated in clinical laboratories worldwide from 2013 to 2017","volume":"64","author":"Morrissey","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1177\/10600280221085551","article-title":"Versus Efficacy of eravacycline best previously available therapy for adults with pneumonia due to difficult-to-treat resistant (DTR)","volume":"56","author":"Scott","year":"2022","journal-title":"Ann. Pharmacother."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.jgar.2020.08.021","article-title":"Comparative efficacy and safety of combination therapy with high-dose sulbactam or colistin with additional antibacterial agents for multiple drug-resistant and extensively drug-resistant Acinetobacter baumannii infections: A systematic review and network","volume":"24","author":"Liu","year":"2021","journal-title":"J. Glob. Antimicrob. Resist."},{"key":"ref_61","first-page":"819","article-title":"Successful Treatment of Carbapenem-Resistant Acinetobacter baumannii Meningitis with Sulbactam-Durlobactam","volume":"79","author":"Tamma","year":"2024","journal-title":"Clin. Infect. Dis."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1002\/phar.2802","article-title":"Sulbactam-durlobactam: A novel \u03b2-lactam-\u03b2-lactamase inhibitor combination targeting carbapenem-resistant Acinetobacter baumannii infections","volume":"43","author":"Caniff","year":"2023","journal-title":"Pharmacotherapy"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1016\/S1473-3099(23)00184-6","article-title":"Efficacy and safety of sulbactam-durlobactam versus colistin for the treatment of patients with serious infections caused by Acinetobacter baumannii-calcoaceticus complex: A multicentre, randomised, active-controlled, phase 3, non-inferiority clinical trial (ATTACK)","volume":"23","author":"Kaye","year":"2023","journal-title":"Lancet Infect. Dis."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.cmi.2021.11.025","article-title":"European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European society of intensive care medicine)","volume":"28","author":"Paul","year":"2022","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Tamma, P.D., Heil, E.L., Justo, J.A., Mathers, A.J., Satlin, M.J., and Bonomo, R.A. (2024). Infectious Diseases Society of America 2024 guidance on the treatment of antimicrobial-resistant Gram-negative infections. Clin Infect Dis., ciae403.","DOI":"10.1093\/cid\/ciae403"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"e0106324","DOI":"10.1128\/aac.01063-24","article-title":"Acinetobacter baumannii treatment strategies: A review of therapeutic challenges and considerations","volume":"69","author":"Kubin","year":"2025","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Huang, C., Chen, I., and Tang, T. (2022). Colistin Monotherapy versus Colistin plus Meropenem Combination Therapy for the Treatment of Multidrug-Resistant Acinetobacter baumannii Infection: A Meta-Analysis. J. Clin. Med., 11.","DOI":"10.3390\/jcm11113239"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"EVIDoa2200131","DOI":"10.1056\/EVIDoa2200131","article-title":"Colistin Monotherapy versus Combination Therapy for Carbapenem-Resistant Organisms","volume":"2","author":"Kaye","year":"2023","journal-title":"NEJM Evid."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1089\/mdr.2016.0279","article-title":"In Vitro Activity of Various Antibiotics in Combination with Tigecycline Against Acinetobacter baumannii: A Systematic Review and Meta-Analysis","volume":"23","author":"Li","year":"2017","journal-title":"Microb. Drug Resist."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"2899","DOI":"10.2147\/IDR.S225518","article-title":"Clinical outcomes of colistin in combination with either 6-G sulbactam or carbapenems for the treatment of extensively drug-resistant Acinetobacter baumannii pneumonia with high MIC to sulbactam, a prospective cohort study","volume":"12","author":"Ungthammakhun","year":"2019","journal-title":"Infect. Drug Resist."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"67","DOI":"10.4103\/ijccm.IJCCM_302_17","article-title":"Colistin versus colistin combined with ampicillin-sulbactam for multiresistant Acinetobacter baumannii ventilator-associated pneumonia treatment: An open-labelprospective study","volume":"22","author":"Makris","year":"2018","journal-title":"Indian. J. Crit. Care Med."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1007\/s40121-022-00597-w","article-title":"Carbapenem-resistant Acinetobacter baumannii: Colonization, Infection and Current Treatment Options","volume":"11","author":"Bartal","year":"2022","journal-title":"Infect. Dis. Ther."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.jinf.2018.07.013","article-title":"Intravenous fosfomycin in patients with liver disease for extensively drug-resistant Gram-negative bacteria","volume":"77","author":"Pyrpasopoulou","year":"2018","journal-title":"J. Infect."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1093\/jac\/dkw115","article-title":"Clinically relevant concentrations of fosfomycin combined with polymyxin B, tobramycin or ciprofloxacin enhance bacterial killing of Pseudomonas aeruginosa, but do not suppress the emergence of fosfomycin resistance","volume":"71","author":"Walsh","year":"2016","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1093\/jac\/dky406","article-title":"Fosfomycin in severe infections due to genetically distinct pan-drug-resistant Gram-negative microorganisms: Synergy with meropenem","volume":"74","author":"Oliveira","year":"2019","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1089\/mdr.2020.0197","article-title":"Pharmacodynamic Analysis of Meropenem and Fosfomycin Combination Against Carbapenem-Resistant Acinetobacter baumannii in Patients with Normal Renal Clearance: Can It Be a Treatment Option?","volume":"27","author":"Lim","year":"2021","journal-title":"Microb. Drug Resist."},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"Assimakopoulos, S.F., Karamouzos, V., Eleftheriotis, G., Lagadinou, M., Bartzavali, C., Kolonitsiou, F., Paliogianni, F., Fligou, F., and Marangos, M. (2023). Efficacy of Fosfomycin-Containing Regimens for Treatment of Bacteremia due to Pan-Drug Resistant Acinetobacter baumannii in Critically Ill Patients: A Case Series Study. Pathogens, 12.","DOI":"10.3390\/pathogens12020286"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"5598","DOI":"10.1128\/AAC.02435-13","article-title":"Preliminary study of colistin versus colistin plus fosfomycin for treatment of carbapenem-resistant Acinetobacter baumannii infections","volume":"58","author":"Sirijatuphat","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s40121-020-00357-8","article-title":"Efficacy of a Fosfomycin-Containing Regimen for Treatment of Severe Pneumonia Caused by Multidrug-Resistant Acinetobacter baumannii: A Prospective, Observational Study","volume":"10","author":"Russo","year":"2021","journal-title":"Infect. Dis. Ther."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"106825","DOI":"10.1016\/j.ijantimicag.2023.106825","article-title":"Efficacy of cefiderocol- vs colistin-containing regimen for treatment of bacteraemic ventilator-associated pneumonia caused by carbapenem-resistant Acinetobacter baumannii in patients with COVID-19","volume":"62","author":"Russo","year":"2023","journal-title":"Int. J. Antimicrob. Agents."},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"Mantzana, P., Protonotariou, E., Kassomenaki, A., Meletis, G., Tychala, A., Keskilidou, E., Arhonti, M., Katsanou, C., Daviti, A., and Vasilaki, O. (2023). In Vitro Synergistic Activity of Antimicrobial Combination sagainst Carbapenem- and Colistin-Resistant Acinetobacter baumannii and Klebsiella pneumoniae. Antibiotics, 12.","DOI":"10.3390\/antibiotics12010093"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1017\/S095026881200194X","article-title":"Colistin vs. the combination of colistin and rifampicin for the treatment of carbapenem-resistant Acinetobacter baumannii ventilator-associated pneumonia","volume":"141","author":"Aydemir","year":"2013","journal-title":"Epidemiol. Infect."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1093\/cid\/cit253","article-title":"Colistin and rifampicin compared with colistin alone for the treatment of serious infections due to extensively drug-resistant Acinetobacter baumannii: A multicenter, randomized clinical trial","volume":"57","author":"Signoriello","year":"2013","journal-title":"Clin. Infect. Dis."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s40121-014-0051-9","article-title":"A Review of Novel Combinations of Colistin and Lipopeptide or Glycopeptide Antibiotics for the Treatment of Multidrug-Resistant Acinetobacter baumannii","volume":"3","author":"Claeys","year":"2014","journal-title":"Infect. Dis. Ther."},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"Karakonstantis, S., Ioannou, P., Samonis, G., and Kofteridis, D.P. (2021). Systematic Review of Antimicrobial Combination Options for Pandrug-Resistant Acinetobacter baumannii. Antibiotics, 10.","DOI":"10.3390\/antibiotics10111344"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1111\/bph.13706","article-title":"Novel approaches to the treatment of bacterial biofilm infections","volume":"174","author":"Hughes","year":"2017","journal-title":"Br. J. Pharmacol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s13756-022-01131-w","article-title":"Duration of central venous catheter placement and central line-associated bloodstream infections after the adoption of prevention bundles: A two-year retrospective study","volume":"11","author":"Pitiriga","year":"2022","journal-title":"Antimicrob. Resist. Infect. Control"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1086\/599376","article-title":"Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 Update by the Infectious Diseases Society of America","volume":"49","author":"Mermel","year":"2009","journal-title":"Clin. Infect. Dis."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"106752","DOI":"10.1016\/j.mimet.2023.106752","article-title":"The effect of phage-antibiotic combination strategy on multidrug-resistant Acinetobacter baumannii biofilms","volume":"210","author":"Erol","year":"2023","journal-title":"J. Microbiol. Methods"},{"key":"ref_90","doi-asserted-by":"crossref","unstructured":"De Angelis, M., Mascellino, M.T., Miele, M.C., Al Ismail, D., Colone, M., Stringaro, A., Vullo, V., Venditti, M., Mastroianni, C.M., and Oliva, A. (2022). High activity of N-acetylcysteine in combination with \u03b2-lactams against carbapenem-resistant Klebsiella pneumoniae and Acinetobacter baumannii. Antibiotics, 11.","DOI":"10.3390\/antibiotics11020225"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1099\/0022-1317-49-11-1047","article-title":"Effect of EDTA on the resistance of clinical isolates of Acinetobacter baumannii to the bactericidal activity of normal human serum","volume":"49","author":"Solar","year":"2000","journal-title":"J. Med. Microbiol."},{"key":"ref_92","first-page":"1043","article-title":"In vitro effectiveness of colistin, tigecycline and levofloxacin alone and in combination with clarithromycin and\/or heparin as lock solutions against embedded Acinetobacter baumannii strains","volume":"70","author":"Ozbek","year":"2015","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"18097","DOI":"10.1038\/s41598-020-75218-y","article-title":"In vitro activity of biofilm inhibitors in combination with antibacterial drugs against extensively drug-resistant Acinetobacter baumannii","volume":"10","author":"Peng","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"e0048524","DOI":"10.1128\/aac.00485-24","article-title":"Population pharmacokinetic analyses for sulbactam-durlobactam using Phase 1, 2, and 3 data","volume":"69","author":"Cammarata","year":"2025","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"e01968-17","DOI":"10.1128\/AAC.01968-17","article-title":"In Vitro Activity of the Siderophore Cephalosporin, Cefiderocol, against Carbapenem-Nonsusceptible and Multidrug-Resistant Isolates of Gram-Negative Bacilli Collected Worldwide in 2014 to 2016","volume":"62","author":"Hackel","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"S552","DOI":"10.1093\/cid\/ciz828","article-title":"Pharmacokinetic and Pharmacodynamic Profiles of Cefiderocol, a Novel Siderophore Cephalosporin","volume":"69","author":"Katsube","year":"2019","journal-title":"Clin. Infect. Dis."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/S1473-3099(20)30796-9","article-title":"Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): A randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial","volume":"21","author":"Bassetti","year":"2021","journal-title":"Lancet Infect. Dis."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S1473-3099(20)30731-3","article-title":"Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): A randomised, double-blind, phase 3, non-inferiority trial","volume":"21","author":"Wunderink","year":"2021","journal-title":"Lancet Infect. Dis."},{"key":"ref_99","doi-asserted-by":"crossref","unstructured":"Zhan, Y., Mao, W., Zhao, C., Lu, D., Chen, C., Hu, W., and Yang, Q. (2024). Comparison of cefiderocol and colistin-based regimens for the treatment of severe infections caused by carbapenem-resistant Acinetobacter baumannii: A systematic review with meta-analysis and trial sequential analysis. BMC Infect. Dis., 24.","DOI":"10.1186\/s12879-024-09979-6"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"106487","DOI":"10.1016\/j.ijantimicag.2021.106487","article-title":"Intrapulmonary pharmacokinetics of high doses of tigecycline in patients with ventilator-associated pneumonia","volume":"59","author":"Dimopoulos","year":"2022","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1093\/jac\/dkr242","article-title":"Efficacy and safety of tigecycline: A systematic review and meta-analysis","volume":"66","author":"Yahav","year":"2011","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_102","doi-asserted-by":"crossref","unstructured":"Deng, Y., Chen, L., Yue, M., Huang, X., Yang, Y., and Yu, H. (2022). Sulbactam combined with tigecycline improves outcomes in patients with severe multidrug-resistant Acinetobacter baumannii pneumonia. BMC Infect. Dis., 22.","DOI":"10.1186\/s12879-022-07778-5"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"e02371-16","DOI":"10.1128\/AAC.02371-16","article-title":"Pharmacokinetics and Pharmacodynamics of Minocycline against Acinetobacter baumannii in a Neutropenic Murine Pneumonia Model","volume":"61","author":"Zhou","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"S381","DOI":"10.1093\/cid\/ciu593","article-title":"Bad bugs need old drugs: A stewardship program\u2019s evaluation of minocycline for multidrug-resistant Acinetobacter baumannii infections","volume":"59","author":"Goff","year":"2014","journal-title":"Clin. Infect. Dis."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1128\/AAC.02036-13","article-title":"Phase I, open-label, safety and pharmacokinetic study to assess bronchopulmonary disposition of intravenous eravacycline in healthy men and women","volume":"58","author":"Connors","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_106","first-page":"3291","article-title":"New pharmacokinetic\/pharmacodynamic studies of systemically administered colistin against Pseudomonas aeruginosa and Acinetobacter baumannii in mouse thigh and lung infection models: Smaller response in lung infection","volume":"70","author":"Cheah","year":"2015","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/S1473-3099(18)30099-9","article-title":"Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: An open-label, randomised controlled trial","volume":"18","author":"Paul","year":"2018","journal-title":"Lancet Infect. Dis."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.jinf.2018.02.002","article-title":"Intravenous plus inhaled versus intravenous colistin monotherapy for lower respiratory tract infections: A systematic review and meta-analysis","volume":"76","author":"Vardakas","year":"2018","journal-title":"J. Infect."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1093\/jac\/dkq360","article-title":"Randomized controlled trial of nebulized colistimethate sodium as adjunctive therapy of ventilator-associated pneumonia caused by Gram-negative bacteria","volume":"65","author":"Rattanaumpawan","year":"2010","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ijantimicag.2006.08.024","article-title":"Intraventricular or intrathecal use of polymyxins in patients with Gram-negative meningitis: A systematic review of the available evidence","volume":"29","author":"Falagas","year":"2007","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"69","DOI":"10.3109\/00365548.2013.837957","article-title":"Cerebrospinal fluid penetration of tigecycline","volume":"46","author":"Pallotto","year":"2014","journal-title":"Scand. J. Infect. Dis."},{"key":"ref_112","first-page":"103","article-title":"Successful treatment of pan-drug resistant Acinetobacter baumannii nosocomial meningitis\/ventriculitis by combined intravenous and intrathecal colistin-tigecycline administration: A case series","volume":"31","author":"Theofanopoulos","year":"2022","journal-title":"Infez. Med."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1093\/jac\/dkn018","article-title":"Multidrug-resistant Acinetobacter meningitis in neurosurgical patients with intraventricular catheters: Assessment of different treatments","volume":"61","author":"Blanco","year":"2008","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S1473-3099(09)70055-6","article-title":"Management of meningitis due to antibiotic-resistant Acinetobacter species","volume":"9","author":"Kim","year":"2009","journal-title":"Lancet Infect. Dis."},{"key":"ref_115","doi-asserted-by":"crossref","unstructured":"Sollima, A., Rossini, F., Lanza, P., Pallotto, C., Meschiari, M., Gentile, I., Stellini, R., Lenzi, A., Mul\u00e9, A., and Castagna, F. (2024). Role of Cefiderocol in Multidrug-Resistant Gram-Negative Central Nervous System Infections: Real Life Experience and State-of-the-Art. Antibiotics, 13.","DOI":"10.3390\/antibiotics13050453"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1093\/jac\/dkac248","article-title":"Plasma and cerebrospinal fluid concentrations of cefiderocol during successful treatment of carbapenem-resistant Acinetobacter baumannii meningitis","volume":"77","author":"Kufel","year":"2022","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1007\/s10096-025-05077-w","article-title":"Successful treatment of carbapenem-resistant Acinetobacter baumannii meningitis and purulent ventriculitis using cefiderocol combination therapy: A case report and literature review","volume":"44","author":"Wang","year":"2025","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"ofac391","DOI":"10.1093\/ofid\/ofac391","article-title":"Clinical Cure of a Difficult-to-Treat Resistant Pseudomonas aeruginosa Ventriculitis Using Cefiderocol: A Case Report and Literature Review","volume":"9","author":"Marcelo","year":"2022","journal-title":"Open Forum Infect. Dis."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"dlab188","DOI":"10.1093\/jacamr\/dlab188","article-title":"Real-life experience with compassionate use of cefiderocol for difficult-to-treat resistant Pseudomonas aeruginosa (DTR-P) infections","volume":"3","author":"Meschiari","year":"2021","journal-title":"JAC-Antimicrob. Resist."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1093\/jac\/dkac066","article-title":"Cerebrospinal fluid concentrations of cefiderocol during the treatment of extensively drug-resistant Pseudomonas aeruginosa ventriculitis","volume":"77","author":"Bennis","year":"2022","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"e0067425","DOI":"10.1128\/aac.00674-25","article-title":"Pharmacokinetics of sulbactam-durlobactam in patients with Acinetobacter baumannii ventriculitis: A report of two cases","volume":"69","author":"Pouya","year":"2025","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_122","doi-asserted-by":"crossref","unstructured":"Snowdin, J.W., Mercuro, N.J., Madaio, M.P., and Rawlings, S.A. (2024). Case report: Successful treatment of OXA-23 Acinetobacter baumannii neurosurgical infection and meningitis with sulbactam-durlobactam combination therapy. Front. Med., 11.","DOI":"10.3389\/fmed.2024.1381123"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"355","DOI":"10.2165\/00003088-198815060-00001","article-title":"Clinical pharmacokinetics of doxycycline and minocycline","volume":"15","author":"Saivin","year":"1988","journal-title":"Clin. Pharmacokinet."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1080\/1120009X.2020.1812804","article-title":"Infective endocarditis by Acinetobacter species: A systematic review","volume":"33","author":"Ioannou","year":"2021","journal-title":"J. Chemother."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"149","DOI":"10.18683\/germs.2024.1427","article-title":"Infective endocarditis by carbapenem-resistant Gram-negative bacteria\u2014A systematic review","volume":"14","author":"Pitsikakis","year":"2024","journal-title":"Germs"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1111\/j.1469-0691.2004.00910.x","article-title":"Colistin efficacy in an experimental model of Acinetobacter baumannii endocarditis","volume":"10","author":"Pichardo","year":"2004","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_127","first-page":"724","article-title":"Acinetobacter endocarditis: A rare nosocomial infection of native heart valves","volume":"13","author":"Shokouhi","year":"2021","journal-title":"Iran. J. Microbiol."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"449","DOI":"10.4103\/ijn.IJN_130_20","article-title":"Colistin nephrotoxicity: Age and baseline kidney functions hold the key","volume":"31","author":"Prasannan","year":"2021","journal-title":"Indian J. Nephrol."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1007\/s40262-021-01063-5","article-title":"Clinical Pharmacokinetics and Pharmacodynamics of Cefiderocol","volume":"60","author":"Bilal","year":"2021","journal-title":"Clin. Pharmacokinet."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1002\/phar.70042","article-title":"Pharmacokinetics of Sulbactam\/Durlobactam in a Patient with Acute Renal Failure, Severe Obesity, and Carbapenem-Resistant Acinetobacter baumannii Bacteremia: A Case Report","volume":"45","author":"Ilges","year":"2025","journal-title":"Pharmacotherapy"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1097\/FTD.0000000000000941","article-title":"Therapeutic Drug Monitoring of Antibiotic Drugs in Patients Receiving Continuous Renal Replacement Therapy or Intermittent Hemodialysis: A Critical Review","volume":"44","author":"Matusik","year":"2022","journal-title":"Ther. Drug Monit."},{"key":"ref_132","doi-asserted-by":"crossref","unstructured":"Fragkou, P.C., Poulakou, G., Blizou, A., Blizou, M., Rapti, V., Karageorgopoulos, D.E., Koulenti, D., Papadopoulos, A., Matthaiou, D.K., and Tsiodras, S. (2019). The Role of Minocycline in the Treatment of Nosocomial Infections Caused by Multidrug, Extensively Drug and Pandrug Resistant Acinetobacter baumannii: A Systematic Review of Clinical Evidence. Microorganisms, 7.","DOI":"10.3390\/microorganisms7060159"},{"key":"ref_133","unstructured":"(2024, July 20). FDA Label, Available online: https:\/\/nctr-crs.fda.gov\/fdalabel\/ui\/search."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1002\/phar.70010","article-title":"A review of antibiotic safety in pregnancy\u20132025 update","volume":"45","author":"Nguyen","year":"2025","journal-title":"Pharmacotherapy"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"e00002-21","DOI":"10.1128\/AAC.00002-21","article-title":"Population Pharmacokinetics and Outcomes of Critically Ill Pediatric Patients Treated with Intravenous Colistin at Higher Than Recommended Doses","volume":"65","author":"Antachopoulos","year":"2021","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_136","first-page":"555","article-title":"Appropriate use of colistin in neonates, infants and children: Interim guidance","volume":"38","author":"Chibabhai","year":"2023","journal-title":"S. Afr. J. Infect. Dis."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"68","DOI":"10.4103\/jmedsci.jmedsci_221_24","article-title":"Managing drug-resistant Acinetobacter baumannii infection in premature infants","volume":"45","author":"Zeng","year":"2025","journal-title":"J. Med. Sci."},{"key":"ref_138","first-page":"123","article-title":"Use of Tigecycline in Pediatric Patients with Infections Predominantly due to Extensively Drug-Resistant Gram-Negative Bacteria","volume":"6","author":"Iosifidis","year":"2017","journal-title":"J. Pediatr. Infect. Dis. Soc."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"e811","DOI":"10.1016\/j.ijid.2012.07.006","article-title":"Risk factors for carbapenem non-susceptibility and mortality in Acinetobacter baumannii bacteremia in children","volume":"16","author":"Punpanich","year":"2012","journal-title":"Int. J. Infect. Dis."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"piaf004","DOI":"10.1093\/jpids\/piaf004","article-title":"Suggested Dosing of Select \u03b2-lactam Agents for the Treatment of Antimicrobial-Resistant Gram-Negative Infections in Children","volume":"14","author":"Lockowitz","year":"2025","journal-title":"J. Pediatr. Infect. Dis. Soc."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"e02529-16","DOI":"10.1128\/AAC.02529-16","article-title":"WCK 5107 (Zidebactam) and WCK 5153 Are Novel Inhibitors of PBP2 Showing Potent \u201c\u03b2-Lactam Enhancer\u201d Activity against Pseudomonas aeruginosa, Including Multidrug-Resistant Metallo-\u03b2-Lactamase-Producing High-Risk Clones","volume":"61","author":"Moya","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"e00948-18","DOI":"10.1128\/AAC.00948-18","article-title":"Assessment of the In Vivo Efficacy of WCK 5222 (Cefepime-Zidebactam) against Carbapenem-Resistant Acinetobacter baumannii in the Neutropenic Murine Lung Infection Model","volume":"62","author":"Avery","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"e01931-18","DOI":"10.1128\/AAC.01931-18","article-title":"In Vivo Efficacy of Humanized WCK 5222 (Cefepime-Zidebactam) Exposures against Carbapenem-Resistant Acinetobacter baumannii in the Neutropenic Thigh Model","volume":"63","author":"Avery","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_144","doi-asserted-by":"crossref","unstructured":"Katsarou, A., Stathopoulos, P., Tzvetanova, I.D., Asimotou, C.-M., and Falagas, M.E. (2025). \u03b2-Lactam\/\u03b2-Lactamase Inhibitor Combination Antibiotics Under Development. Pathogens, 14.","DOI":"10.3390\/pathogens14020168"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1080\/23744235.2024.2379492","article-title":"Phage therapy: An alternative treatment modality for MDR bacterial infections","volume":"56","author":"Pal","year":"2024","journal-title":"Infect. Dis."},{"key":"ref_146","doi-asserted-by":"crossref","unstructured":"Alrafaie, A. (2025). Harnessing phages to tackle antimicrobial resistance: A Saudi Arabian perspective. Front. Cell. Infect. Microbiol., 15.","DOI":"10.3389\/fcimb.2025.1702890"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s00284-023-03295-z","article-title":"Acinetobacter baumannii Bacteriophage: Progress in Isolation, Genome Sequencing, Preclinical Research, and Clinical Application","volume":"80","author":"Li","year":"2023","journal-title":"Curr. Microbiol."},{"key":"ref_148","doi-asserted-by":"crossref","unstructured":"Tan, X., Chen, H., Zhang, M., Zhao, Y., Jiang, Y., Liu, X., Huang, W., and Ma, Y. (2021). Clinical Experience of Personalized Phage Therapy Against Carbapenem-Resistant Acinetobacter baumannii Lung Infection in a Patient with Chronic Obstructive Pulmonary Disease. Front. Cell. Infect. Microbiol., 11.","DOI":"10.3389\/fcimb.2021.631585"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"118502","DOI":"10.1016\/j.biopha.2025.118502","article-title":"Bacteriophage antimicrobial therapy: From mechanism exploration to biomedical applications","volume":"193","author":"Zhao","year":"2025","journal-title":"Biomed. Pharmacother."},{"key":"ref_150","doi-asserted-by":"crossref","unstructured":"Mahlapuu, M., H\u00e5kansson, J., Ringstad, L., and Bj\u00f6rn, C. (2016). Antimicrobial Peptides: An Emerging Category of Therapeutic Agents. Front. Cell. Infect. Microbiol., 6.","DOI":"10.3389\/fcimb.2016.00194"},{"key":"ref_151","doi-asserted-by":"crossref","unstructured":"Michaeli, J., Mandel, S., Maximov, S., Zazoun, J., Savoia, P., Kothari, N., Valmont, T., Ferrari, L., Duncan, L.R., and Hawser, S. (2022). In Vitro and In Vivo Antimicrobial Activity of the Novel Peptide OMN6 against Multidrug-Resistant Acinetobacter baumannii. Antibiotics, 11.","DOI":"10.3390\/antibiotics11091201"},{"key":"ref_152","doi-asserted-by":"crossref","unstructured":"Rajapaksha, D.C., Edirisinghe, S.L., Nikapitiya, C., Whang, I., and De Zoysa, M. (2023). The Antimicrobial Peptide Octopromycin Suppresses Biofilm Formation and Quorum Sensing in Acinetobacter baumannii. Antibiotics, 12.","DOI":"10.3390\/antibiotics12030623"},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"20283","DOI":"10.1021\/acs.jmedchem.5c01360","article-title":"Therapeutic Potential of Novel Antimicrobial Peptide Pap12-6-10: Mechanisms of Antibacterial and Anti-inflammatory Action Against Gram-Negative Sepsis","volume":"68","author":"Kim","year":"2025","journal-title":"J. Med. Chem."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"e154484","DOI":"10.5812\/ijpr-154484","article-title":"Evaluation of Antimicrobial Activity of Novel Chimeric M-PEX12 Peptide Against Acinetobacter baumannii","volume":"24","author":"Rakhshani","year":"2025","journal-title":"Iran J. Pharm. Res."},{"key":"ref_155","doi-asserted-by":"crossref","unstructured":"Dijksteel, G.S., Ulrich, M.M.W., Middelkoop, E., and Boekema, B.K.H.L. (2021). Review: Lessons Learned from Clinical Trials Using Antimicrobial Peptides (AMPs). Front. Microbiol., 12.","DOI":"10.3389\/fmicb.2021.616979"},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"6270","DOI":"10.1128\/AAC.01520-13","article-title":"Epidemiology of bloodstream infections caused by Acinetobacter baumannii and impact of drug resistance to both carbapenems and ampicillin-sulbactam on clinical outcomes","volume":"57","author":"Chopra","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1016\/j.cmi.2020.03.035","article-title":"Colistin plus meropenem for carbapenem-resistant Gram-negative infections: In vitro synergism is not associated with better clinical outcomes","volume":"26","author":"Nutman","year":"2020","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1186\/s13643-024-02695-x","article-title":"Efficiency of combination therapy versus monotherapy for the treatment of infections due to carbapenem-resistant Gram-negative bacteria: A systematic review and meta-analysis","volume":"13","author":"Lai","year":"2024","journal-title":"Syst. Rev."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.jgar.2019.12.009","article-title":"Resistance to ceftazidime-avibactam and underlying mechanisms","volume":"22","author":"Wang","year":"2020","journal-title":"J. Glob. Antimicrob. Resist."}],"container-title":["Pathogens"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-0817\/15\/1\/81\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T10:57:08Z","timestamp":1768215428000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-0817\/15\/1\/81"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,12]]},"references-count":159,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1]]}},"alternative-id":["pathogens15010081"],"URL":"https:\/\/doi.org\/10.3390\/pathogens15010081","relation":{},"ISSN":["2076-0817"],"issn-type":[{"value":"2076-0817","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,12]]}}}